scholarly journals Preparation of Poly-Lactic-Co-Glycolic Acid Nanoparticles in a Dry Powder Formulation for Pulmonary Antigen Delivery

Pharmaceutics ◽  
2021 ◽  
Vol 13 (8) ◽  
pp. 1196
Author(s):  
Regina Scherließ ◽  
Julia Janke
Keyword(s):  
Particle Size ◽  
Glycolic Acid ◽  
Double Emulsion ◽  
Antigen Delivery ◽  
Dry Powder ◽  
Antigen Uptake ◽  
Emulsion Method ◽  
Powder Formulation ◽  
Particulate Antigen ◽  
Antigen Release

One of the key requirements for successful vaccination via the mucosa is particulate antigen uptake. Poly-lactic-co-glycolic acid (PLGA) particles were chosen as well-known model carriers and ovalbumin (OVA) as the model antigen. Aiming at application to the respiratory tract, which allows direct interaction of the formulation with the mucosal immune system, this work focuses on the feasibility of delivering the antigen in a nanoparticulate carrier within a powder capable of pulmonary delivery. Further requirements were adequate antigen encapsulation in order to use the characteristics of the particulate carrier for (tunable) antigen release, and capability of the production process for industrialisation (realisation in industry). For an effective particulate antigen uptake, nanoparticles with a size of around 300 nm were prepared. For this, two production methods for nanoparticles, solvent change precipitation and the double emulsion method, were evaluated with respect to antigen incorporation, transfer to a dry powder formulation, redispersion and antigen release characteristics. A spray drying step was included in the production procedure in order to obtain a respirable powder with an aerodynamic particle size of between 0.5 and 5 μm. The dried products were characterised for particle size, dispersibility and aerodynamic behaviour, as well as for immune response and cytotoxicity in cell culture models. It could be shown that the double emulsion method is suitable to prepare nanoparticles (270 nm) and to incorporate the antigen. By modifying the production method to prepare porous particles, it was possible to obtain an acceptable antigen release while maintaining an antigen load of about 10%. By the choice of polyvinyl alcohol as a stabiliser, nanoparticles could be dried and redispersed without further excipients and the production steps were capable of realisation in industry. Aerodynamic characteristics were good with a mass median aerodynamic diameter of 3.3 µm upon dispersion from a capsule-based inhaler.

scholarly journals FORMULATION AND EVALUATION OF ISORHAMNETIN LOADED POLY LACTIC-CO-GLYCOLIC ACID NANOPARTICLES

2017 ◽  
Vol 10 (11) ◽  
pp. 177
Author(s):  
Kandakumar Settu ◽  
Manju Vaiyapuri
Keyword(s):  
Particle Size ◽  
Glycolic Acid ◽  
Polymeric Nanoparticles ◽  
Double Emulsion ◽  
Spherical Shape ◽  
Particle Size Analysis ◽  
Size Analysis ◽  
Characteristic Variety ◽  
Sem Image ◽  
Flexible Technology

  Objective: The aim of the present study was formulation and evaluation of isorhamnetin loaded poly lactic-co-glycolic acid (PLGA) polymeric nanoparticles (NPs).Methods: The present study was designed to incorporate the isorhamnetin in PLGA formulation by double emulsion solvent evaporation method, which offers a dynamic and flexible technology for enhancing drug solubility due to their biphasic characteristic, variety in design, composition and assembly. Synthesized isorhamnetin-PLGA NPs were characterized by Fourier transform infrared spectroscopy (FTIR), scanning electron microscopy (SEM), and particle size analyzer. We tested the efficacy of isorhamnetin-PLGA NPs in HepG2 cell lines.Results: From the FTIR result, we concluded that -C-N-, -C=C-, N-H, C-N, N-O, O-H, and C-H are the functional groups present in isorhamnetin-PLGA NPs, SEM image shows spherical shape of particles. The particle size analysis result shows 255-342 nm range of particles. Isorhamnetin-PLGA NPs significantly enhanced (p<0.05) the antiproliferative effect when compared to the plain drug.Conclusion: This study concluded that the newly formulated NP drug delivery systems of isorhamnetin provided an insight into the therapeutic effectiveness of the designed formulation for the treatment of chemotherapy.

Effects of particle size and adding sequence of fine lactose on the deposition of salbutamol sulphate from a dry powder formulation

1999 ◽  
Vol 182 (2) ◽  
pp. 133-144 ◽  
Author(s):  
Xian Ming Zeng ◽  
Gary Peter Martin ◽  
Seah-Kee Tee ◽  
Abeer Abu Ghoush ◽  
Christopher Marriott
Keyword(s):  
Particle Size ◽  
Dry Powder ◽  
Salbutamol Sulphate ◽  
Powder Formulation

One-pot preparation of polymer microspheres with different porous structures to sequentially release bio-molecules for cutaneous regeneration

2018 ◽  
Vol 6 (4) ◽  
pp. 820-826 ◽  
Author(s):  
Pingyun Yuan ◽  
Xinyu Qiu ◽  
Ronghua Jin ◽  
Yongkang Bai ◽  
Shiyu Liu ◽  
...  
Keyword(s):  
Glycolic Acid ◽  
Sol Gel ◽  
Double Emulsion ◽  
Polymer Microspheres ◽  
Porous Structures ◽  
One Pot ◽  
Emulsion Method ◽  
Gel Method ◽  
Sol Gel Method ◽  
Sequential Release

Herein, we reveal a double emulsion method combining the sol–gel method to prepare poly(lactic-co-glycolic acid) microspheres with different porous structures for sequential release of two types of biomolecules.

Cell-Penetrating Peptide-Mediated Nanovaccine Delivery

2021 ◽  
Vol 22 ◽  
Author(s):  
Jizong Jiang
Keyword(s):  
Immune System ◽  
Immune Responses ◽  
Cell Penetrating Peptide ◽  
Antigen Delivery ◽  
Efficient Manner ◽  
Antigen Uptake ◽  
Cell Penetrating ◽  
The Stability ◽  
Antigen Presenting

Abstract: Vaccination with small antigens, such as proteins, peptides, or nucleic acids, is used to activate the immune system and trigger the protective immune responses against a pathogen. Currently, nanovaccines are undergoing development instead of conventional vaccines. The size of nanovaccines is in the range of 10–500 nm, which enables them to be readily taken up by cells and exhibit improved safety profiles. However, low-level immune responses, as the removal of redundant pathogens, trigger counter-effective activation of the immune system invalidly and present a challenging obstacle to antigen recognition and its uptake via antigen-presenting cells (APCs). In addition, toxicity can be substantial. To overcome these problems, a variety of cell-penetrating peptide (CPP)-mediated vaccine delivery systems based on nanotechnology have been proposed, most of which are designed to improve the stability of antigens in vivo and their delivery into immune cells. CPPs are particularly attractive components of antigen delivery. Thus, the unique translocation property of CPPs ensures that they remain an attractive carrier with the capacity to deliver cargo in an efficient manner for the application of drugs, gene transfer, protein, and DNA/RNA vaccination delivery. CPP-mediated nanovaccines can enhance antigen uptake, processing, and presentation by APCs, which are the fundamental steps in initiating an immune response. This review describes the different types of CPP-based nanovaccines delivery strategies.

Sign in / Sign up

Export Citation Format

Share Document